紫杉醇联合卡铂静脉化疗两种给药方案治疗晚期卵巢上皮性癌临床分析

Clinical analysis of two dosage regimens of paclitaxel plus carboplatin intravenous chemotherapy in the treatment of advanced epithelial ovarian cancer

目的:探讨紫杉醇联合卡铂静脉化疗2种不同给药方案治疗晚期卵巢上皮性癌患者的近期疗效及不良反应。方法:回顾性分析郑州大学第二附属医院妇产科2011年1月至2013年1月初次诊断为卵巢上皮性癌并接受化疗的136例患者的临床资料。同一天给药组62例,分2 d给药组74例,对2组患者的近期疗效及化疗毒副反应进行分析。结果:2种给药方案治疗晚期卵巢上皮性癌的近期疗效差异无统计学意义,2组患者各级骨髓抑制分布差异有统计学意义(P=0.000),2组患者各级恶心呕吐分布差异有统计学意义(P=0.004),2组患者各级肝功损伤分布差异无统计学意义(P=0.321),2组患者各级肾功损伤分布差异无统计学意义(P=0.086),2组患者各级神经感觉异常分布差异无统计学意义(P=0.280)。结论:静脉分2 d给药这种方案可以作为晚期卵巢上皮性癌患者(紫杉醇+卡铂)方案化疗可替代的理想的给药方案。

Objective：To explore short term curative effects and adverse reactions of two different dosage regimens of paclitaxel plus carboplatin intravenous chemotherapy in the treatment of advanced epithelial ovarian cancer. Methods：Clinical data of 136 patients who were diagnosed as epithelial ovarian cancer and accepted chemotherapy in the department of obstetrics and gynecology in the Second Affiliated Hospital of Zhengzhou University from January 2011 to January 2013 were retrospectively analyzed. There were 62 cases in one day medication group and 74 cases in two days medication group. Short term curative effects and adverse reactions of chemotherapy in two groups were compared and analyzed. Results：There was no statistically significant difference in short term curative effect between two therapeutic regimens for advanced epithelial ovarian cancer. There were statistically significant differences in distribution of bone marrow at all levels between two groups（P=-0.000）. Distribution of nausea and vomiting at all levels were statistically different between two groups（P=0.004）. There was no statistically significant difference in liver damage distribution at all levels between two groups（P=0.321 ）. There was no statistically significant difference in distribution of renal injury at all levels between two groups（P=0.086）. Distribution of abnormal nerve sensation at all levels was not statistically different between two groups （P= 0.280）. Conclusions：Dosage regimen in two days medication group can replace paclitaxel plus carboplatin chemotherapy in the treatment of advanced epithelial ovarian cancer.